EXTON, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. , announced that it will be presenting to investors and other interested parties at the upcoming Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York on November 7, 2005. “Rodman & Renshaw’s Techvest Conference has been gathering great momentum especially in the Life Sciences area. We are pleased to have been selected to speak as a representative of the specialty pharma sector,” said Jack E. Stover, President and CEO. The Conference will be held at The New York Palace Hotel, and is expected to include approximately 290 presenting companies with an audience of more than 2,000 attendees.
The Company’s presentation is scheduled for 3:30 p.m. Eastern Time. Investors, analysts and the general public may listen to the live and archived audio portion of the presentation by accessing http://www.wsw.com/webcast/rrshq7/antr.ob/
About Antares Pharma
Antares Pharma is a specialized pharma product development company with patented drug delivery systems and injectable device engineering capabilities. Antares’ current technology platforms include its ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/Vision(R) reusable needle-free injection devices (Our new Medi-Jector Vision website can be viewed online at http://www.mediject.com). Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares’ product pipeline will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.
Antares has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy. Its needle-free injector system is distributed in more than 30 countries for the administration of insulin and is marketed for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that it expects will form the basis of its specialized pharma program.
Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Additional information is available online at http://www.antarespharma.com. Information included on the Company’s websites is not incorporated herein by reference or otherwise.
Antares Pharma, Inc.
CONTACT: Steve Chizzik or Ira Weingarten, Equity Communications,+1-973-912-0980; or Jack E. Stover, President and CEO, +1-610-458-6200, orLawrence M. Christian, CFO and Vice President, Finance, +1-610-458-6200,both of Antares Pharma, Inc.
